Lymphangiogenic therapy prevents cardiac dysfunction by ameliorating inflammation and hypertension.

Consistent with the gene expression analysis, immunohistochemistry also showed a trend toward increased Lyve1-positive lymphatic vessel density in angiotensin II-infused kidneys, and VEGFCc156s treatment ameliorated this response ( Figure 6—figure supplement 1G and H ).

also in 53,322 other papers